ly2880070
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02632448)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Rectal Neoplasms · Phase 1/Phase 2
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Serine/threonine-protein kinase Chk1INHIBITOR
CHEK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ly2880070
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05275426 | Phase 2 | Mar 2, 2022 | Memorial Sloan-Kettering Cancer Center |
| NCT02632448 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | Esperas Pharma Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Esperas Pharma Inc. | For profit | 1 | 1 | 1 | 2016 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1